Blog Posts - Genotype 5



Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of...
by Hepatitis C Research and News on Apr 25, 2015

My Treatment Approach to Chronic Hepatitis C Virus (Genotypes 1–6)

Article in Press Mitchell L. Shiffman, MD, April G. Long, NP, Amy James, FNP, Phillip Alexander, NP Published Online: May 24, 2014 DOI: http://dx.doi.org/10.1016/j.mayocp.2014.04.013 Publication stage: In Press Corrected Proof...
by Hepatitis C Research and News on Jun 14, 2014

Clinical Trial: A Phase III Evaluation of Daclatasvir + Sofosbuvir in Genotype 1-6 Chronic HCV Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant

This study is not yet open for participant recruitment. Verified January 2014 by Bristol-Myers Squibb Sponsor: Bristol-Myers Squibb Information provided by (Responsible Party): Bristol-Myers Squibb ClinicalTrials.gov Identifier: NCT02032875 F...
by Hepatitis C Research and News on Jan 11, 2014

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

Alimentary Pharmacology & Therapeutics Early View (Online Version of Record published before inclusion in an issue) Review Article You have free access to this content J. M. Wantuck1, A. Ahmed2, M. H. Nguyen2,* Article first published online...
by Hepatitis C Research and News on Nov 20, 2013

Video: Sofosbuvir, ribavirin combination therapy effective in HCV treatment

Provided by Healio October 23, 2013 SAN DIEGO — Kris Kowdley, MD, reports during the American College of Gastroenterology Annual Scientific Meeting that 12 weeks of sofosbuvir combination therapy was well tolerated and effective in patients with he...
by Hepatitis C Research and News on Oct 23, 2013

FDA Grants Priority Review To Oral Hepatitis C Drug Sofosbuvir, Approval Set For December

Gilead's drug will be the first to hit the market in a new generation of targeted hepatitis C treatments with high cure rates. By Jonathan Weiss, Ph.D. | Jun 10, 2013 10:05 AM EDT Following successful late stage Phase III clinical trials of sofosbu...
by Hepatitis C Research and News on Jun 10, 2013

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 7, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for sofosbuvir, a onc...


Trending Topics

Close